- Home
- LDWY vs POAI Comparison
LDWY vs POAI Comparison
Compare LDWY & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- POAI
- Stock Information
- Founded
- LDWY 1990
- POAI 2002
- Country
- LDWY United States
- POAI United States
- Employees
- LDWY N/A
- POAI N/A
- Industry
- LDWY Advertising
- POAI Industrial Specialties
- Sector
- LDWY Consumer Discretionary
- POAI Health Care
- Exchange
- LDWY Nasdaq
- POAI Nasdaq
- Market Cap
- LDWY 9.2M
- POAI 8.9M
- IPO Year
- LDWY 1991
- POAI N/A
- Fundamental
- Price
- LDWY $4.90
- POAI $0.89
- Analyst Decision
- LDWY
- POAI Hold
- Analyst Count
- LDWY 0
- POAI 1
- Target Price
- LDWY N/A
- POAI N/A
- AVG Volume (30 Days)
- LDWY 6.5K
- POAI 93.9K
- Earning Date
- LDWY 08-18-2025
- POAI 08-12-2025
- Dividend Yield
- LDWY N/A
- POAI N/A
- EPS Growth
- LDWY N/A
- POAI N/A
- EPS
- LDWY N/A
- POAI N/A
- Revenue
- LDWY $42,183,000.00
- POAI $1,729,269.00
- Revenue This Year
- LDWY N/A
- POAI $486.27
- Revenue Next Year
- LDWY N/A
- POAI $65.50
- P/E Ratio
- LDWY N/A
- POAI N/A
- Revenue Growth
- LDWY 425.12
- POAI 24.17
- 52 Week Low
- LDWY $3.02
- POAI $0.55
- 52 Week High
- LDWY $5.53
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- LDWY 50.82
- POAI 38.00
- Support Level
- LDWY $4.85
- POAI $0.85
- Resistance Level
- LDWY $5.12
- POAI $0.91
- Average True Range (ATR)
- LDWY 0.16
- POAI 0.06
- MACD
- LDWY -0.05
- POAI -0.00
- Stochastic Oscillator
- LDWY 7.84
- POAI 4.12
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two industries: Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.